The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

For those conducting R&D into developing a new form of weight loss therapy, the most obvious target is the development of an oral treatment. As such, there is a race by major obesity drug ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...

Now that Mounjaro has been authorised for use on the NHS, it will be key that access to specialist weight loss services is ...

A new study shows semaglutide medications, such as Ozempic and Wegovy, may be effective in treating hidradenitis suppurativa ...

Research explores how excessive sugar consumption can drive systemic inflammation, disrupt the gut and oral microbiomes, and ...

Nasdaq-listed Amneal Pharmaceuticals, which already operates multiple manufacturing facilities in Gujarat, is further ...

Investors appear enthused by BioAge’s focus on the red-hot obesity drug space, where both Novo Nordisk and Eli ... in two Phase II trials designed to assess the oral apelin receptor (APJ) agonist’s ...

Shares of Pfizer PFE rose 2.17% on Oct. 7 after a report from The Wall Street Journal stated that activist investor Starboard ...